Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PSI-7977 + Daclatasvir +/- Ribavirin in Chronic HCV
NCT01359644Phase 2Completed
- Sponsor
- Bristol Myers Squibb
- Start
- Jun 2011
- Primary completion
- Jan 2013
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 2, randomised, open-label trial of sofosbuvir and daclatasvir in hepatitis C (HCV) (10 arms), sponsored by Bristol Myers Squibb. Primary endpoint: Sustained Virologic Response at Post Treatment Week 12. Started Jun 2011; status: completed.
02
Drugs
sofosbuvirdaclatasvir
03
Conditions
hepatitis C (HCV)
Beyond the preview
Go deeper on NCT01359644.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01359644.